26 March 2021 in Medicine
Introduction: Myxofibrosarcoma (MFS) is a locally aggressive tumor and has the potential to be fatal because of distant metastasis. Immunotherapy targeting either programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently shown a curative effect on multiple cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma. Although the immunotherapy has been applied in sarcoma, there is little information about the efficiency to treat metastatic MFS. Patient concerns: A 42-year-old male presented to the clinic with a mass in the left thigh. Mass resection and ligament replacement surgery were performed. Diagnoses: The patient was diagnosed as high-grade MFS (federation nationale des centres de lutte contre le cancer, Grade 3) with pulmonary metastasis. Interventions: In the past few years, he was treated with surgery, chemoradiotherapy, and Anlotinib (an angiogenesis inhibitor), but the metastatic lesion continued to progress. About 40% to 50% of tumor cells in his pulmonary tissues were showed positive PD-L1 expression and his tumor mutational burden was 215Muts. Thus, he received Camrelizumab (PD-1 inhibitor). Outcomes: Six months after the initiating immunotherapy of Camrelizumab, the size of pulmonary lesions showed marked shrinkage, indicating a partial response. After a follow-up of 18 months, the patient remained in good condition without progressive disease. Conclusion: This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.
20 September 2026 in Cancer Medicine
Introduction: Pulmonary metastasis in high‐grade conventional osteosarcoma remains a leading cause of treatment failure and mortality. Traditional monitoring methods are insufficient for early detection. This study aims to develop and validate an interpretable machine learning (ML) model using multi‐dimensional data from electronic medical records (EMR) to predict the early risk of pulmonary metastasis in high‐grade conventional osteosarcoma patients. Methods: This retrospective study included data from 522 high‐grade conventional osteosarcoma patients. After rigorous feature selection, 12 independent predictive factors were identified: prothrombin time (PT), international normalized ratio (INR), fibrinogen, globulin, prognostic nutritional index (PNI), eosinophil percentage, monocyte percentage, neutrophil percentage, monocyte count, maximum tumor diameter, gender, and amputation status. Eleven ML models were constructed and compared, with Shapley Additive Explanations (SHAP) analysis applied to enhance model interpretability and clinical transparency. Results: The gradient boosting model exhibited superior performance, achieving an area under the curve (AUC) of 0.891 in the training set and 0.742 in the independent test set. SHAP analysis revealed that tumor maximum diameter was the most influential predictor of pulmonary metastasis risk, while inflammation and coagulation‐related indicators also demonstrated significant contributions. Discussion: The gradient boosting model effectively predicts the early risk of pulmonary metastasis in high‐grade conventional osteosarcoma and provides interpretable risk factors. This model shows potential as a clinical decision support tool, facilitating personalized risk management and precision medicine, aiming to improve patient outcomes.
18 June 2026 in Orthopaedic Surgery
Background: Parosteal osteosarcoma (PAOS) is a rare and low‐grade primary bone malignant tumor that typically occurs in the distal femur. Traditional reconstruction options for distal femur PAOS include distal femoral replacement (DFR), autografts, and allografts, but issues such as functional sacrifice, insufficient mechanical strength, and low bone union rate limit their further clinical application. 3D‐printed prosthesis, due to the matching shape of various bone defects, could be a novel strategy to reconstruct the hemicortical defect after distal femur PAOS tumor resection. In this study, we designed a 3D‐printed strut‐type prosthesis (3DPSP) to repair the hemicortical defect and evaluated the mid‐term effect in distal femur PAOS. Methods: A retrospective analysis was conducted on patients diagnosed with PAOS at the distal femur between April 2018 and January 2021. Six patients received DFR and six patients received customized 3DPSP reconstruction. Clinical outcomes including oncology status, defect lengths, and ranges of motion of the knee, Musculoskeletal Tumor Society (MSTS) scores, and complications were recorded. X‐ray was performed to evaluate the position and stability of the prosthesis and T‐SMART was applied to assess the interface osteointegration between prosthesis and bone. Results: A total of 12 patients were enrolled in this study with an average follow‐up of 42.1 ± 11.8 months, ranging from 22 to 59 months. In the 3DPSP group, the average operation time was 2.3 ± 0.4 h; the intraoperative blood loss was 175.0 ± 82.2 mL. The average range of motion of the knee was 0°–123° and the mean MSTS score was 28.3 ± 1.6. Compared to the DFR group, the 3DPSP group exhibited significantly less intraoperative blood loss and superior functional recovery. Conclusions: In this study, we designed a novel 3DPSP to reconstruct the hemicortical defect after distal femur PAOS resection. The mid‐term follow‐up result demonstrated that this prosthesis could be an effective reconstruction option for distal femur PAOS patients because of the restored limb function and favorable bone‐prosthesis integration. Further observation of this novel prosthesis is needed.